Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-a catalytic subunit (encoded by PIK3CA) 1 . They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R). Although the p110-a mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models. Furthermore, clinical trials with PI3K inhibitors have recently been initiated, and it is unknown if their efficacy will be restricted to specific, genetically defined malignancies. In this study, we engineered a mouse model of lung adenocarcinomas initiated and maintained by expression of p110-a H1047R. Treatment of these tumors with NVP-BEZ235, a dual pan-PI3K and mammalian target of rapamycin (mTOR) inhibitor in clinical development, led to marked tumor regression as shown by positron emission tomography-computed tomography, magnetic resonance imaging and microscopic examination. In contrast, mouse lung cancers driven by mutant Kras did not substantially respond to single-agent NVP-BEZ235. However, when NVP-BEZ235 was combined with a mitogen-activated protein kinase kinase (MEK) inhibitor, ARRY-142886, there was marked synergy in shrinking these Kras-mutant cancers. These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and, when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.
To generate mice with inducible expression of human p110a H1047R, we injected a DNA segment consisting of seven direct repeats of the tetracycline operator (Tet-op) sequence, followed by human PIK3CA complementary DNA encoding the H1047R mutation and the SV40 polyadenosine tail into FVB/N fertilized eggs as previously described 2, 3 .
Ten Tet-op-PIK3CA founders were identified and then crossed to clara cell secretory protein (CCSP)-reverse tetracycline transactivator protein (rtTA) mice (in which expression of rtTA is specifically targeted to type II alveolar epithelial cells 4 ) to generate inducible, double-transgenic mouse cohorts harboring both the activator and the responder transgenes 4, 5 . The Tet-op-PIK3CA copy numbers from the two most commonly used founders (13 and 121) were determined by quantitative real-time PCR ( Supplementary Fig. 1a online).
To induce expression of p110-a H1047R in mouse lung epithelial cells, we administered doxycycline chow to double-transgenic mice from each of the founder lines, monitored them for labored breathing and imaged dyspneic mice with magnetic resonance imaging (MRI) to identify abnormalities. Three founder lines (13, 121 and 3011) had labored breathing and MRI images consistent with lung tumors after 12, 26 and 60 weeks, respectively (data not shown). These mice were killed, and gross inspection revealed multiple small tumor nodules. Histological analyses revealed mixed adenocarcinomas with bronchioloalveolar features ( Fig. 1a ). As founder line 13 showed the shortest latency period, it was used for subsequent experiments.
The inducibility of the PIK3CA mutant transgene expression in the lung was evaluated at the RNA level by RT-PCR. PIK3CA H1047R expression was readily observed after 12 weeks of doxycycline administration ( Supplementary Fig. 1b ). Doxycycline withdrawal led to a loss of mutant PIK3CA expression ( Supplementary Fig. 1b ). We observed expression of mutant p110-a protein in PI3K immunoprecipitations only from the double-transgenic mice induced with doxycycline ( Supplementary Fig. 1c ). Of note, expression of the transgene did not substantially increase total p110-a protein expression ( Supplementary Fig. 1c ). This is expected, as p110-a that is not bound to p85 is unstable, and any p110-a expressed in excess of p85 is rapidly degraded [6] [7] [8] .
Withdrawal of doxycycline led to rapid and marked tumor regression, thereby demonstrating that these established lung tumors require continual expression of p110-a H1047R (Fig. 1b) . After doxycycline withdrawal, histological examination showed focal pulmonary fibrosis and scarring and no evidence of cancer ( Fig. 1c ). Of note, complete tumor regression was also observed in the other founder line (121) that was examined for reversibility ( Supplementary Fig. 2 online) . Thus, these lung tumors require continual p110-a H1047R expression for their maintenance.
To inhibit PI3K signaling in vivo, we treated mice with NVP-BEZ235, a potent dual pan-PI3K-mTOR inhibitor currently under clinical development ( Supplementary Fig. 3a online) 9 . This drug blocks the kinase activity of all four p110 isoforms and mutant p110-a H1047R with similar potencies 9 . To identify a dose that adequately blocks PI3K in lung tissue, we treated control mice with one dose in the range of 30 mg kg -1 to 52.5 mg kg -1 and harvested the lungs either 3 h or 8 h later. At most of the dose levels examined, NVP-BEZ235 induced suppression of PI3K signaling, as indicated by a decrease in phosphorylated Akt (P-Akt) at both Ser473 and Thr308 ( Supplementary Fig. 3b ). Akt is a serine-threonine kinase that is phosphorylated and activated in response to PI3K signaling. We then evaluated whether this compound could inhibit PI3K signaling in the lung tumors induced by the p110-a H1047R mutant. One oral treatment of 35 mg kg -1 NVP-BEZ235 led to substantial suppression of Akt, ribosomal protein S6 and 4E-binding protein-1 phosphorylation in these mouse tumors ( Fig. 2a and Supplementary Methods online).
We next evaluated the clinical efficacy of NVP-BEZ235 against p110-a H1047R-induced mouse lung tumors. Tumor responses were assessed by MRI, positron emission tomography-computed tomography (PET-CT) scans and histological analyses. Doxycycline was administered to double-transgenic mice, and MRI screening identified mice with established tumors before the initiation of treatment. We observed that 4 d of treatment with NVP-BEZ235 at 35 mg kg -1 d -1 led to a substantial reduction in the 18 fluorodeoxyglucose ( 18 FDG) avidity of the tumor, as measured by PET imaging, and also led to a marked decrease in their size, as judged by CT ( Fig. 2b and Supplementary Movie 1 online for three-dimensional reconstruction PET images). These data support the notion that 18 FDG-PET imaging may be a major pharmacodynamic marker for efficacy of PI3K inhibitors in the clinic. Histopathological analysis after short-term treatments showed decreased cellularity and increased interstitial thickening within the residual tumor nodule, with no evidence of adenocarcinoma ( Fig. 2c) .
Because NVP-BEZ235 is a dual PI3K-mTOR inhibitor, we determined whether the effects of this compound were due to its inhibition of TOR complex-1 (TORC1) (mTOR-Raptor). Therefore, we treated mice with established PIK3CA-mutated tumors with rapamycin. Treatment with rapamycin effectively blocked TORC1 in these tumors, as evidenced by a loss of S6 phosphorylation ( Supplementary Fig. 4 online). However, unlike NVP-BEZ235, rapamycin did not shrink these tumors (Figs. 2d,e). These findings suggest that the activity of NVP-BEZ235 in these tumors is not solely due to TORC1 inhibition.
A recent study revealed that p110-a is required for lung tumorigenesis in the LA2 Kras G12D mouse model 10 . This is a model of mutant Kras lung cancers in which a silenced Kras G12D mutant allele is activated by spontaneous homologous recombination at a low frequency, resulting in lung adenocarcinomas 11 . In that study, mice were generated in which the endogenous Pik3ca gene was mutated in the Ras binding domain. This mutation abrogated the ability of Kras G12D to induce lung tumors. Using a different genetic approach, we also observed that loss of PI3K signaling hindered Kras-induced lung tumorigenesis. We crossed the Lox-Stop-Lox (LSL) Kras G12D mice to mice with genetic deletion of the p85 PI3K regulatory subunits (encoded by Pik3r1 and Pik3r2). We previously used p85 knockouts to genetically ablate PI3K signaling in different tumor models 12 . The experiments were performed on a Pik3r2 À/À background, and the Pik3r1 allele was flanked by flox sites. Inhaled adenoviral Cre leads to both the deletion of Pik3r1 and activation of Kras G12D. We observed that loss of both Pik3r1 alleles inhibited tumorigenesis ( Fig. 3a) . Of note, these genetic experiments evaluate the role of PI3K in mutant Kras-induced tumor development. To more closely mirror clinical treatment of individuals with cancer, we evaluated whether PI3K signaling is necessary for the maintenance of established Kras-driven tumors. We used both the tetracycline-inducible Tet-op-Kras G12D transgenic model 4 H1047R, those derived from Kras G12D did not shrink in response to single-agent NVP-BEZ235, as indicated by PET-CT or MRI images (Fig. 3b,c and Supplementary Fig. 5a online) . However, NVP-BEZ235 decreased Akt phosphorylation in these lungs, as determined by western blot (Fig. 3d ) and immunohistochemical analyses (described below). These results suggest that PI3K may be required for Kras-induced tumorigenesis but may be less crucial for tumor maintenance. Indeed, this concept may reconcile our results with another recent study that showed that a different PI3K inhibitor, PX-866, blocked both the development of new Kras G12D-induced tumors and inhibited growth of the Kras G12D-driven atypical adenomatous hyperplasias and early adenoma 13 . Although both the Kras tumor model mouse strains and the p110-a H1047R tumor model mouse strain are on similar mixed genetic backgrounds, it remains conceivable that subtle differences in genetic background may have affected their responsiveness to PI3K inhibitors. However, the data with the Kras tumor models clearly underscore the notion that blocking tumorigenesis is not equivalent to treating a cancer that is already established.
Recently, it has become evident that cancers respond markedly to therapies targeting receptor tyrosine kinases when inhibition of the receptor tyrosine kinase leads to loss of both PI3K and extracellular signal-related kinase signaling [14] [15] [16] [17] . To recapitulate this effect in the Kras-mutant lung tumors, we treated the mice with a combination of PI3K and MEK inhibitors. Whereas treatment of the Kras-mutant mice with the MEK inhibitor, ARRY-142886 (ref. 18 ), led to only modest tumor regression, the combination led to marked synergistic tumor regression ( Fig. 4a,b) , and pathological analyses at the completion of treatment revealed only scant remnants of tumor nodules ( Supplementary Fig. 5b ). After 2 d of the combination treatment, there was marked downregulation of PI3K, extracellular signal-related kinase and downstream signaling as indicated by western blot analyses and immunohistochemistry (Fig. 4c,d) . Of note, we invariably detected low-level P-Akt staining in the Kras G12D mouse nodules that was lost upon treatment of the mouse with NVP-BEZ235 (Fig. 4d) .
KRAS-mutated lung cancers remain a huge cancer problem, as they comprise 20-30% of non-small cell lung cancers. Currently, there are no effective targeted therapies for this subset of cancers. In fact, the presence of KRAS mutations only serves to identify those cancers that are likely not to respond to targeted therapies. The data in this study clearly show that the combination of PI3K and MEK inhibitors may be a very potent combination for such cancers. We hope this study spurs efforts to combine these classes of inhibitors for KRAS-mutated cancers.
There is not yet sufficient clinical data to determine whether PI3K inhibitors will be powerful therapeutic agents as single-agent cancer therapies for patients or whether they will be effective only when combined with other targeted therapies. However, it is tempting to speculate that cancers that harbor activating mutations in PIK3CA or loss of PTEN may be particularly sensitive to PI3K inhibitors. Although this study suggests that cancers with PIK3CA mutations may respond to PI3K inhibitors, human cancers with PIK3CA mutations often harbor other known oncogenic mutations such as mutations in KRAS (colon cancers) and HER2 (encoding human epidermal growth factor-2) amplification (breast cancer) [19] [20] [21] . These concomitant oncogenic genetic changes may affect the tumors' responsiveness to PI3K inhibitors and, possibly, may necessitate combinations of treatments, as was the case for effective treatment of the Kras-mutated mouse lung cancers.
METHODS
Plasmids for transgenic mice. We purchased human PI3KCA from Open-Biosystems and introduced the H1047R point mutation with the QuickChange kit from Stratagene, following the manufacturer's instructions. We cloned the gene encoding PI3KCA H1047R into the BamHI and HindIII site of pTRE-tight (Clontech), resulting in plasmid pTRE-tight-H1047R. We gel-purified the XhoI-released fragment from pTRE-tight-H1047R for pronuclei injection at the transgenic core facility at Dana-Farber Cancer Institute.
Mouse cohorts. We crossed Tet-op-PI3KCA H1047R mice to CCSP-rtTA mice (generously provided by J. Whitsett). We gave the double-transgenic mice (Tet-op-PI3KCA H1047R and CCSP-rtTA) a doxycycline diet (c11300-2000i, Researchdiets) beginning at 22 d of age. We used MRI to determine tumor burden as previously described 2 . Tet-op-Kras mice were generously provided by H. Varmus. LSL Kras G12D mice were kindly provided by T. Jacks. All of the mice used in these studies were of mixed genetic backgrounds (mostly B6 and FVB), and treatment studies were performed on littermate controls. We housed all mice in the pathogen-free environment at the Harvard School of Public Health. We handled the mice in strict accord with good animal practice, as defined by the Center for Animal Resources and Comparative Medicine (ARCM) at Harvard Medical School, and all mouse work was done with ARCM approval.
Cancer therapy using inhibitors. We reconstituted the dual PI3K-mTOR inhibitor, NVP-BEZ235-AN (Novartis Institutes for Biomedical Research), in one volume of N-methyl-2-pyrrolidone (69118, Fluka) and then added nine volumes of PEG300 (81160, Fluka). We gave the mice the dosages indicated in the figure legends by oral gavage. The dosage indicates the amount of the free base. We purchased the MEK inhibitor ARRY-142886 (AZD6244) from commercial sources (Otava Chemicals) and reconstituted it in 0.5% methyl cellulose (Fluka) and 0.4% polysorbate (Tween 80; Fluka) and administered it at the dosages indicated in the figure legends by oral gavage. We prepared rapamycin stock solution at a concentration of 50mg ml -1 in 100% ethanol, diluted it to 1 mg ml -1 immediately before use with 5% polyethylene glycol 400 (vol/vol) and 5% Tween 80 (vol/vol), mixed it thoroughly and then administered it by intraperitoneal injection at the dosages indicated in the figure legends. After treatment, we analyzed mice by MRI and PET-CT at different time points to determine the change in tumor burden. Sectioning was performed by the Department of Pathology at Brigham and Women's Hospital.
Positron emission tomography-computed tomography scans. We imaged the mice with a Siemens Inveon PET-CT scanner 1 h after injection of approximately 500 mCi of 18 FDG. We performed the PET scan first. The PET scanner was set to finish after 600 million events were recorded. List mode files were rebinned in three dimensions, and the subsequent sinograms were reconstructed using filtered back projection for quantification. Certain images were also reconstructed using two-dimensional ordered subset expectation maximization for better visualization. Immediately after the PET scan, we acquired the CT scan. We set the X-ray source to a voltage and current of 70 kVp and 500 mA, respectively, and we positioned it relative to the charge-coupled device detector camera and mouse such that the effective pixel size was 59.73 mm isotropically. We monitored the mouse's breathing rate with a BioVet (M2M Imaging), and we used the breathing signal to gate the CT. We acquired 360 projections with an exposure time of 320 ms. All projection data were reconstructed using filtered backprojection. The images were interpolated bilinearly and filtered with a Shepp-Logan filter for higher resolution.
Magnetic resonance imaging and tumor volume measurement. We performed MRI measurements as described previously 2 . Briefly, we made the measurements with a 4.7T Bruker Avance horizontal bore system equipped with a 200-mm inner diameter gradient set capable of 30 G cm -1 gradient strength or with a 7T Bruker Pharmascan system. We anesthetized the mice with 1% isoflurane in an oxygen-air mixture. We monitored the respiratory and cardiac rates of the mice with Biotrig Software (4.7T) or an SA Instruments monitoring device (Stony Brook, for 7T system). We imaged the mice on the 4.7T system with rapid acquisition with relaxation enhancement (RARE) sequence (repetition time (TR) ¼ 2000 ms; effective echo time (TE) effect ¼ 25 ms) in the coronal and axial planes with a 1-mm slice thickness and with the number of slices sufficient to cover the entire lungs and with a matrix size of 128 Â 128 and field of view of 2.5 Â 2.5 cm 2 . With the same geometry as described above, we also imaged the mice with a gradient echo fast imaging sequence (TR ¼ 180 ms, TE ¼ 2.2 ms) with respiratory and cardiac gating in both the coronal and the axial planes. For images acquired on the 7T system, we performed RARE sequences after the intravenous administration of 0.3 mmol kg -1 gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA; Magnevist) in both coronal and axial planes with TR ¼ 600 ms, TE ¼ 15.3 ms, FOV 5.4 Â 4.0 cm, matrix size 256 Â 192, slice thickness 1.0 mm, 12 number of excitations, for a voxel size of 0.2 Â 0.2 Â 1.0 mm. Using the RARE sequence scans, we performed volume measurements of the tumors using in-house custom software.
Statistical analyses. We compared tumor volumes of mice treated with different therapies using a two-sided Student's exact t-test. A P value of less than 0.05 was considered statistically significant.
Note: Supplementary information is available on the Nature Medicine website.
